---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007044"
form_type: "8-K"
ticker: "BLGO"
cik: "0000880242"
company_name: "BIOLARGO, INC."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T21:16:10.641548+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M

## Summary
- Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.
- Net loss of $15.2M vs. $4.3M in prior year; cash balance $3.9M at year end.
- Engineering services revenue from third parties grew 98% to $2.0M.
- Subsidiary Clyra Medical secured first stocking order for ViaCLYR wound irrigation solution.
- PFAS treatment system installed in New Jersey; PFAS breakthrough featured in Chemical Engineering.

## SEC filing metadata
- accession: 0001437749-26-007044
- form_type: 8-K
- ticker: BLGO
- cik: 0000880242
- company_name: BIOLARGO, INC.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/880242/000143774926007044/0001437749-26-007044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/880242/000143774926007044/blgo20260305_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007044
- JSON: https://secwatch.observer/filing/0001437749-26-007044.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.